Fractyl Effects of Single Dose Human GLP-1 Pancreatic Gene Therapy Transgene v. Semaglutide in Mouse Model

 Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control.

The human GLP-1 transgene sequence used in RJVA-001 was administered to eight-week-old db/db mice with established disease and resulted in up to 50% blood sugar lowering and 11% weight loss vs vehicle at four weeks after a single administration, compared to 32% glucose lowering and 2% weight loss vs vehicle with chronic semaglutide.

These results with a native, short half-life human GLP-1 sequence to be used in RJVA-001 build upon earlier results with a prototype transgene GLP-1 analogue.

https://www.globenewswire.com/news-release/2024/03/12/2844941/0/en/UPDATE-Fractyl-Health-Announces-New-Results-From-Its-Rejuva-Platform-Demonstrating-Potent-and-Durable-Effects-of-a-Single-Dose-of-a-Human-GLP-1-Pancreatic-Gene-Therapy-Transgene-Co.html